The response rates to surveys among breast cancer patients using different manners of distribution: A prospective study of integrated rehabilitation.

Authors

null

Mateja Kurir Borovcic

Institute of Oncology Ljubljana, Ljubljana, Slovenia

Mateja Kurir Borovcic , Zlatka Mavric , Anamarija Mozetic , Tina Zagar , Lorna Zadravec Zaletel , Nada Rotovnik Kozjek , Denis Mlakar Mastnak , Simona Borstnar , Nikola Besic

Organizations

Institute of Oncology Ljubljana, Ljubljana, Slovenia, Institute of Oncology, Ljubljana, Slovenia

Research Funding

Other
ARRS and Ministry of Health of the Republic of Slovenia

Background: Communication with breast cancer patients is crucial within individualised integrated rehabilitation, where the patients are at the centre of the provided health care services. Anonymous surveys could be used as one of the tools to check the needs of patients, the effectiveness of various aspects of the interventions offered and to obtain valuable feedback from patients. Our aim was to determine which manner of conducting anonymous surveying among breast cancer patients would be most suitable for improving the health service of individualized integrated rehabilitation. Methods: The subjects of our prospective study were 600 females (29-65 (mean 52) years of age), who participated in the pilot study on the individualized integrated rehabilitation of breast cancer patients receiving treatment at Institute of Oncology Ljubljana in 2019-2022. Questionnaires of implemented surveys were anonymous with different manners of distribution and on three different topics. The first survey was conducted via standard post sending questionnaires on papers to the patients to inquire about their satisfaction with the provided services after the conclusion of their treatment. The second survey was conceded via email, sending online questionnaires to inquire about appropriateness of interventions and patients' opinions about spa treatment. The third survey was conducted half via email and half via text message on mobile phone (SMS) to inquire about the most suitable terms of the regular physical activity during oncological treatment. The survey response rate was calculated as the number of valid surveys received (numerator) divided by the number of surveys distributed (denominator). If all questions were not answered, the survey was invalid. Results: There was a significant difference in the response rate of the patients to the anonymous surveys, depending on the manner of distribution of the survey. The response rate of patients who got questionnaires by regular mail were 51%, 28% and 13% if received by e-mail and 27% if sent via SMS. The difference in the response rate in the survey on physical activity, received by email or by SMS, was statistically significant (p= 0,0026). Conclusions: The highest response rate of breast cancer patients was received by sending the questionnaires via regular post. Clinical trial information: V3-1906.

Response rate of breast cancer patients to surveys with different mannersof distribution.

Survey on satisfaction – regular postSurvey on
the spa –
via email
Survey on physical activity – via emailSurvey on physical activity – via mobile phone (SMS)
Number of surveys send600276150150
Number of surveys received306772041
Response rate51.0%27.9%13.3%27,3%

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Breakthrough

Session Type

Poster Session

Session Title

Poster Session B

Track

Gastrointestinal Cancer,Gynecologic Cancer,Head and Neck Cancer,Quality of Care,Genetics/Genomics/Multiomics,Healthcare Equity and Access to Care,Healthtech Innovations,Models of Care and Care Delivery,Population Health,Viral-Mediated Malignancies

Sub Track

Other Technology and Innovations

Clinical Trial Registration Number

V3-1906

Citation

JCO Global Oncology 9, 2023 (suppl 1; abstr 138)

DOI

10.1200/GO.2023.9.Supplement_1.138

Abstract #

138

Poster Bd #

J3

Abstract Disclosures